Literature DB >> 21598740

Contribution of thebesian veins to the physiologic shunt in anesthetized man.

M B Ravin, R M Epstein, J R Malm.   

Abstract

The purpose of the present study is to quantitate the contribution of the thebesian veins to the total physiologic shunt in anesthetized man. The subjects were adults, free of septal defects, who were undergoing a variety of open-heart procedures for the correction of diseased valves. The studies were completed following thoracotomy but prior to the placement of catheters. Subjects were anesthetized, intubated, and ventilated with a constant-volume respirator. Prior to blood sampling 100% oxygen was administered for at least 3 min. Samples were simultaneously drawn from the left atrium and the aorta and analyzed for Po2 with a microelectrode which had been calibrated with tonometered blood. Only studies in which aortic Po2 exceeded 150 mm Hg were accepted. Pco2 and pH were also measured. From the difference in Po2 between left atrium and aorta the contribution of left ventricular thebesian veins to the physiologic shunt was calculated using a modification of the shunt equation. Values found ranged from 0.12 to 0.43% of the aortic flow. Mixed thebesian oxygen content was assumed to be 6 vol % in this calculation, but the value chosen can be shown not to be critical.

Entities:  

Mesh:

Substances:

Year:  1965        PMID: 21598740     DOI: 10.1152/jappl.1965.20.6.1148

Source DB:  PubMed          Journal:  J Appl Physiol        ISSN: 0021-8987            Impact factor:   3.531


  2 in total

1.  [The distribution analysis of ventilation, perfusion, and O2 diffusing capacity in the lung, through concentration changes for 3 inspiratory gases. 3. Tests on adolescents, elderly people, and pregnant women].

Authors:  H R Vogel; G Thews; V Schulz; H J von Mengden
Journal:  Pflugers Arch       Date:  1968       Impact factor: 3.657

2.  All's Not Well(ens) that Ends Well: Case Study of Significant Thebesian Veins Mimicking Wellens Syndrome.

Authors:  Keith Frank
Journal:  Spartan Med Res J       Date:  2020-06-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.